Upstream Bio, Inc.
NASDAQ:UPBBiotechnology
+$0.10 today
- Market cap
- $114.01M
- Beta
- 1.11
- P/E (TTM)
- -2.2
- EPS (TTM)
- -$2.89
Volume 1.24M
Average 0.66M
UPB EBITDA Margin
EBITDA as a percentage of revenue.
Upstream Bio, Inc.NASDAQ: UPB
EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026
EBITDA Margin widens to -3920.9%
EBITDA Margin was -3920.9% in Q1 FY2026, up 889.5 pp from a year earlier. On a trailing-twelve-month basis it was -4713.1%, down 1269.6 pp year over year. Over 3 fiscal years it narrowed by 3050.7 pp.
Context
- EBITDA Margin widened in 1 of the last 3 fiscal years.
- FY2025 was the lowest level in the 4 fiscal years shown.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 5 analysts of -6446.7% for the fiscal year ending Dec 2026, down from -5019.4% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -3920.9%+2426.7 pp QoQ
- Last fiscal yearDec 2025
- -5019.4%-2373.2 pp YoY
- LTMMar 2026
- -4713.1%-1269.6 pp YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -5019.4%
- Year-over-year change
- -2373.2pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -5019.4% | -2373.2pp |
| FY2024 | 2024-12-31 | -2646.3% | -1785.9pp |
| FY2023 | 2023-12-31 | -860.4% | +1108.4pp |
| FY2022 | 2022-12-31 | -1968.7% | — |
EBITDA Margin vs competitors
How UPB compares with its peers on the latest reported figures
- UPB's LTM Mar 2026 EBITDA Margin of -4713.1% is the lowest of the 8 companies compared; the peer median is -309.5%.
- Its year-over-year change of -1269.6 pp is the lowest of 7, against a peer median of +249.2 pp.
- Over three fiscal years its change of -3050.7 pp compares with a peer median of +1995.1 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | -7.1% | -51.3 pp | +81.6 pp | |
| LTM Mar 2026 | -74.8% | +669.1 pp | — | |
| LTM Mar 2026 | -243.2% | -144.4 pp | +3681.3 pp | |
| LTM Sep 2026 | -309.5% | — | — | |
| LTM Mar 2026 | -581.9% | +549.6 pp | +308.9 pp | |
| LTM Jun 2026 | -2742.3% | +927.4 pp | +20440.0 pp | |
| FY2025 | -3704.3% | -575.9 pp | — | |
UPBUpstream Bio, Inc. | LTM Mar 2026 | -4713.1% | -1269.6 pp | -3050.7 pp |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding UPB) | -309.5% | +249.2 pp | +1995.1 pp | |
Competitors are the stored peer set for UPB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 1.21M | 2.38M | 2.37M | 2.85M |
| Cost of Revenue | 0 | 0 | 0 | 0 |
| Gross Profit | 1.21M | 2.38M | 2.37M | 2.85M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% |
| Research & Development | 18.66M | 31.8M | 62.97M | 136.81M |
| Selling, General & Admin | 6.46M | 10.7M | 17.17M | 26.41M |
| Operating Expenses | 25.12M | 42.49M | 80.13M | 163.22M |
| Depreciation & Amortization | 7K | 60K | 89K | 188K |
| EBITDA | (23.86M) | (20.48M) | (62.72M) | (143.26M) |
| EBITDA Margin | -1968.7% | -860.4% | -2646.3% | -5019.4% |
| Operating Income | (23.91M) | (40.11M) | (77.76M) | (160.36M) |
| Operating Margin | -1972.7% | -1685.5% | -3281.2% | -5618.8% |
| Interest Income | 205K | 4.17M | 12.12M | 16.93M |
| Interest Expense | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 41K | 19.58M | 14.96M | 16.92M |
| Income Before Tax | (23.87M) | (20.54M) | (62.81M) | (143.44M) |
| Pre-Tax Margin | -1969.3% | -862.9% | -2650.0% | -5026.0% |
| Income Tax Expense | 0 | 0 | 0 | 0 |
| Net Income | (23.87M) | (20.54M) | (62.81M) | (143.44M) |
| Net Margin | -1969.3% | -862.9% | -2650.0% | -5026.0% |
| EPS (Basic) | (0.66) | (1.05) | (1.49) | (2.66) |
| EPS (Diluted) | (0.66) | (1.05) | (1.49) | (2.66) |
| Weighted Avg Shares | 36.32M | 36.32M | 51.34M | 53.85M |
| Weighted Avg Shares (Diluted) | 36.32M | 36.32M | 51.34M | 53.85M |
Upstream Bio, Inc.
NASDAQ:UPB
Intrinsic Alpha fair value
Locked
Current Price
$2.08
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.